MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2025.1685424

Медицинская библиотека · Frontiers in endocrinology · 2025

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers impact on the gut microbiome: a systematic review.

Wang Elisabeth M, Shremo Msdi Abdulwhab, Quach Vy N, Nguyen Selena Q, Quach Emily, Jo Jinhee, Eubank Taryn A, Garey Kevin W, Rosario Natalie

СтатьяСистематический обзорПеревод в очереди

Аннотация

BACKGROUND

Inhibition of the renin-angiotensin system (RAS) may influence gut microbial composition and blood pressure, yet current evidence remains limited. This review examines how angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) modify gut microbiome composition, function, and blood pressure regulation.

METHODS

We conducted a systematic search of MEDLINE and EMBASE from inception to September 2025 using terms including "human," "rat," "angiotensin converting enzyme inhibitor," "angiotensin receptor blocker," and "gut microbiome." Eligible studies were required to report changes in microbiome diversity, bacterial composition, or short-chain fatty acids (SCFAs) associated with ACEi/ARB treatment across animal or human models. Data extraction and risk of bias assessments were performed independently by multiple reviewers.

RESULTS

After deduplication, 642 retrieved articles were filtered and nine met inclusion criteria (eight in rodent models, one human study). ACEi/ARB administration in animals was associated with increased microbial diversity, restoration of intestinal oxygen balance, and enrichment of SCFA-producing anaerobic genera such as Bifidobacterium, Bacteroides, Blautia, and Akkermansia. In the human study, ACEi/ARB use did not significantly alter microbial diversity, but decreased populations of facultative aerobic pathogens including Staphylococcus and Enterobacterales. Functionally, prolonged RAS inhibition elevated levels of acetate, propionate, and butyrate, and enhanced gut barrier integrity while attenuating inflammatory signaling. The human study was found to have a moderate risk of bias.

CONCLUSIONS

ACEi and ARB therapies appear to reshape gut microbiome structure and metabolic function, promoting SCFA-producer expansion, improved gut barrier integrity, and modulation of microbial taxa linked to inflammation and hypertension. However, human data is limited, and further transitional research is needed to confirm these findings.

Для цитирования: Wang Elisabeth M, Shremo Msdi Abdulwhab, Quach Vy N, Nguyen Selena Q, Quach Emily, Jo Jinhee, Eubank Taryn A, Garey Kevin W, Rosario Natalie. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers impact on the gut microbiome: a systematic review.. Frontiers in endocrinology. 2025. DOI: 10.3389/fendo.2025.1685424.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.